News of the study comes days after it emerged an NHS trial will use AI to interpret MRI scans from men suspected of having ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

NHS hospitals are set to test an artificial intelligence tool, ArteraAI Prostate Biopsy Assay, designed to diagnose and guide treatment decisions for prostate cancer.

The trial will test 10,000 scans at up to 15 hospitals across the country and will be rolled out nationally if successful.

Under current best practice guidelines, patients should receive an MRI and biopsy within 7 days of an urgent GP referral for suspected prostate cancer but depending on the capacity of radiologists ...

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important ...

Results of Five Years of a Cancer Patient Navigation Training Program for Limited-Resource Settings in the Caribbean and Africa The study was performed in three stages at three Nigerian tertiary ...

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...